? This supplemental research proposal for clinical resident research experience seeks to validate tomography algorithms, instrumentation, and imaging agents developed under the parent grant, """"""""Small animal fluorescence enhanced optical imaging."""""""" Using a dual-labeled, optical and nuclear imaging agent targeted to the alpha-v-beta-3 integrin, we propose to compare a """"""""gold-standard"""""""" of preclinical tomography, micro- SPECT with time-dependent fluorescence tomography. Owing to the short duration of the proposed research project, we will deploy existing technology developments to assess the molecular specificity of an optical/nuclear integrin-targeting imaging agent and assess its biodistribution within an orthotopic animal model of integrin expressing metastatic melanoma. Specifically we will: 1. Assess the molecular specificity of imaging agents c(KRGDf)-IRDye800, 1111n-c(KRGDf), and 1111n- c(KRDGf)-IRDye800 through competitive binding and determination of IC50 in cell cultures of integrin positive M21 and integrin negative M21-L; 2. Perform SPECT and fluorescence-enhanced optical imaging of c(KRGDf)-IRDye800, 1111n-c(KRGDf), and 111 ln-c(KRDGf)-IRDye800 and compare imaging figures of merit as SUV, TBR, and SNR; 3. Assess the biodistribution of agents via comparison of tomographic images with co-registered micro-CT; and 4. Use autoradiography, fluorescence microscopy, and immunohistochemistry to assess the tissue location of targeting agents. This project will not focus upon technology development, but instead will use established and newly developed technologies. If successful, this project will provide the first validation of optical tomography in a preclinical model of metastatic cancer. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
3R01EB003132-05S1
Application #
7139330
Study Section
Special Emphasis Panel (ZEB1-OSR-C (M1))
Program Officer
Erim, Zeynep
Project Start
2003-09-16
Project End
2007-06-30
Budget Start
2006-07-13
Budget End
2007-06-30
Support Year
5
Fiscal Year
2006
Total Cost
$112,500
Indirect Cost
Name
Baylor College of Medicine
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Joshi, Amit; Rasmussen, John C; Sevick-Muraca, Eva M et al. (2008) Radiative transport-based frequency-domain fluorescence tomography. Phys Med Biol 53:2069-88
Sampath, Lakshmi; Wang, Wei; Sevick-Muraca, Eva M (2008) Near infrared fluorescent optical imaging for nodal staging. J Biomed Opt 13:041312
Melancon, Marites P; Wang, Wei; Wang, Yuetang et al. (2007) A novel method for imaging in vivo degradation of poly(L-glutamic acid), a biodegradable drug carrier. Pharm Res 24:1217-24
Sampath, Lakshmi; Kwon, Sunkuk; Ke, Shi et al. (2007) Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med 48:1501-10
Adams, Kristen E; Ke, Shi; Kwon, Sunkuk et al. (2007) Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 12:024017
Wang, Wei; Ke, Shi; Kwon, Sunkuk et al. (2007) A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem 18:397-402
Rasmussen, John C; Joshi, Amit; Pan, Tianshu et al. (2006) Radiative transport in fluorescence-enhanced frequency domain photon migration. Med Phys 33:4685-700
Gurfinkel, Michael; Ke, Shi; Wang, Wei et al. (2005) Quantifying molecular specificity of alphavbeta3 integrin-targeted optical contrast agents with dynamic optical imaging. J Biomed Opt 10:034019
Houston, Jessica P; Ke, Shi; Wang, Wei et al. (2005) Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J Biomed Opt 10:054010